The Latest Cardiac and Vascular News
MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the digital leader in preventive heart health, today released its inaugural Why Heart Health Matters Report, which examines the toll that cardiovascular disease (CVD) takes on employers, health plans, and the people they serve. The report surveyed 300 benefits leaders at large employers and health plans […]
MOUNTAIN VIEW, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT®) code beginning January 1, 2024. The new code, designated by The American Medical Association (AMA), supports FFRCT […]
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the Auryon XL Catheter, […]
BETHESDA, Md.–(BUSINESS WIRE)–CorVista Health, Inc., a leading digital health company dedicated to improving cardiovascular disease diagnosis announces expansion of their Medical Advisory Board with the appointment of Dr. Anjali Tiku Owens. “Dr. Tiku Owens’ wealth of experience and expertise in cardiology, particularly in genetic cardiomyopathy and novel therapies, will be […]
REHOVOT, Israel–(BUSINESS WIRE)–Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it received Breakthrough Device Designation from the US Food and Drug Administration for ShortCut™ – the world’s first dedicated leaflet modification device facilitating valve-in-valve Transcatheter Aortic Valve Replacement […]
COSTA MESA, Calif., Jan. 19, 2024 /PRNewswire/ — CerraCap Ventures, a leading venture capital firm in healthcare innovation, has invested in Acorai, a cutting-edge company in cardiovascular health technology. The investment will boost the development and deployment of Acorai’s novel…
ABBOTT PARK, Ill., Jan. 18, 2024 /PRNewswire/ — Abbott (NYSE: ABT) today announced the first global procedures have been conducted using the company’s new Volt™ Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib). Over 30 patients were recently treated in Australia as part of […]
Non-Dilutive Financing Provides Comprehensive Solution to Address Debt Maturities and Provide Flexibility to Further Optimize Capital Structure ATLANTA, Jan. 18, 2024 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease,…
Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company’s 2024 Annual […]
TEMPE, Ariz.–(BUSINESS WIRE)– #AbdominalAorticAneurysm–Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease and improve patients’ lives, today announced initiation of a Phase II/III clinical trial (stAAAble) to investigate the safety and efficacy of the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System in patients with infrarenal abdominal aortic aneurysms (AAAs), maximum diameter 3.5 – 5.0cm. The Nectero EAST System is a single-use,
